1
|
Xu S, Shiomi H, Yamashita Y, Koyama S, Horie T, Baba O, Kimura M, Nakashima Y, Sowa N, Hasegawa K, Suzuki A, Suzuki Y, Kimura T, Ono K. CRISPR-Cas9-guided amplification-free genomic diagnosis for familial hypercholesterolemia using nanopore sequencing. PLoS One 2024; 19:e0297231. [PMID: 38507394 PMCID: PMC10954175 DOI: 10.1371/journal.pone.0297231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Accepted: 01/01/2024] [Indexed: 03/22/2024] Open
Abstract
Familial hypercholesterolemia is an inherited disorder that remains underdiagnosed. Conventional genetic testing methods such as next-generation sequencing (NGS) or target PCR are based on the amplification process. Due to the efficiency limits of polymerase and ligase enzymes, these methods usually target short regions and do not detect large mutations straightforwardly. This study combined the long-read nanopore sequencing and CRISPR-Cas9 system to sequence the target DNA molecules without amplification. We originally designed and optimized the CRISPR-RNA panel to target the low-density lipoprotein receptor gene (LDLR) and proprotein convertase subtilisin/kexin type 9 gene (PCSK9) from human genomic DNA followed by nanopore sequencing. The average coverages for LDLR and PCSK9 were 106× and 420×, versus 1.2× for the background genome. Among them, continuous reads were 52x and 307x, respectively, and spanned the entire length of LDLR and PCSK9. We identified pathogenic mutations in both coding and splicing donor regions in LDLR. We also detected an 11,029 bp large deletion in another case. Furthermore, using continuous long reads generated from the benchmark experiment, we demonstrated how a false-positive 670 bp deletion caused by PCR amplification errors was easily eliminated.
Collapse
Affiliation(s)
- Sijia Xu
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Hiroki Shiomi
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yugo Yamashita
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Satoshi Koyama
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Takahiro Horie
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Osamu Baba
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masahiro Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yasuhiro Nakashima
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Naoya Sowa
- Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan
| | - Koji Hasegawa
- Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan
| | - Ayako Suzuki
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier, Tokyo University, Tokyo, Japan
| | - Yutaka Suzuki
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier, Tokyo University, Tokyo, Japan
| | - Takeshi Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
2
|
Tsuji S, Otani C, Horie T, Watanabe S, Baba O, Sowa N, Ide Y, Kashiwa A, Makiyama T, Imai H, Nakashima Y, Yamasaki T, Xu S, Matsushita K, Suzuki K, Zou F, Kume E, Hasegawa K, Kimura T, Kakizuka A, Ono K. KUS121, a VCP modulator, has an ameliorating effect on acute and chronic heart failure without calcium loading via maintenance of intracellular ATP levels. Biomed Pharmacother 2024; 170:115850. [PMID: 38091636 DOI: 10.1016/j.biopha.2023.115850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 10/26/2023] [Accepted: 11/05/2023] [Indexed: 01/10/2024] Open
Abstract
AIMS As heart failure (HF) progresses, ATP levels in myocardial cells decrease, and myocardial contractility also decreases. Inotropic drugs improve myocardial contractility but increase ATP consumption, leading to poor prognosis. Kyoto University Substance 121 (KUS121) is known to selectively inhibit the ATPase activity of valosin-containing protein, maintain cellular ATP levels, and manifest cytoprotective effects in several pathological conditions. The aim of this study is to determine the therapeutic effect of KUS121 on HF models. METHODS AND RESULTS Cultured cell, mouse, and canine models of HF were used to examine the therapeutic effects of KUS121. The mechanism of action of KUS121 was also examined. Administration of KUS121 to a transverse aortic constriction (TAC)-induced mouse model of HF rapidly improved the left ventricular ejection fraction and improved the creatine phosphate/ATP ratio. In a canine model of high frequency-paced HF, administration of KUS121 also improved left ventricular contractility and decreased left ventricular end-diastolic pressure without increasing the heart rate. Long-term administration of KUS121 to a TAC-induced mouse model of HF suppressed cardiac hypertrophy and fibrosis. In H9C2 cells, KUS121 reduced ER stress. Finally, in experiments using primary cultured cardiomyocytes, KUS121 improved contractility and diastolic capacity without changing peak Ca2+ levels or contraction time. These effects were not accompanied by an increase in cyclic adenosine monophosphate or phosphorylation of phospholamban and ryanodine receptors. CONCLUSIONS KUS121 ameliorated HF by a mechanism totally different from that of conventional catecholamines. We propose that KUS121 is a promising new option for the treatment of HF.
Collapse
Affiliation(s)
- Shuhei Tsuji
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Chiharu Otani
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Takahiro Horie
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Shin Watanabe
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Osamu Baba
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan; Preemptive Medicine and Lifestyle Disease Research Center, Kyoto University Hospital Kyoto, 606-8507, Japan
| | - Naoya Sowa
- Division of Translational Research, National Hospital Organization, Kyoto Medical Center, 1-1 Fukakusa Mukaihata-cho, Fushimi-ku, Kyoto 612-8555, Japan
| | - Yuya Ide
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Asami Kashiwa
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Takeru Makiyama
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Hirohiko Imai
- Department of Systems Science, Graduate School of Informatics, Kyoto University, Kyoto 606-8501, Japan
| | - Yasuhiro Nakashima
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Tomohiro Yamasaki
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Sijia Xu
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Kazuki Matsushita
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Keita Suzuki
- Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Fuquan Zou
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Eitaro Kume
- Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Koji Hasegawa
- Preemptive Medicine and Lifestyle Disease Research Center, Kyoto University Hospital Kyoto, 606-8507, Japan
| | - Takeshi Kimura
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
| | - Akira Kakizuka
- Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies and Solution Oriented Research for Science and Technology, Kyoto 606-8501, Japan.
| | - Koh Ono
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
| |
Collapse
|
3
|
Miyagawa S, Horie T, Nishino T, Koyama S, Watanabe T, Baba O, Yamasaki T, Sowa N, Otani C, Matsushita K, Kojima H, Kimura M, Nakashima Y, Obika S, Kasahara Y, Kotera J, Oka K, Fujita R, Sasaki T, Takemiya A, Hasegawa K, Kimura T, Ono K. Inhibition of microRNA-33b in humanized mice ameliorates nonalcoholic steatohepatitis. Life Sci Alliance 2023; 6:e202301902. [PMID: 37263777 PMCID: PMC10235800 DOI: 10.26508/lsa.202301902] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 05/23/2023] [Accepted: 05/24/2023] [Indexed: 06/03/2023] Open
Abstract
Nonalcoholic steatohepatitis (NASH) can lead to cirrhosis and hepatocellular carcinoma in their advanced stages; however, there are currently no approved therapies. Here, we show that microRNA (miR)-33b in hepatocytes is critical for the development of NASH. miR-33b is located in the intron of sterol regulatory element-binding transcription factor 1 and is abundantly expressed in humans, but absent in rodents. miR-33b knock-in (KI) mice, which have a miR-33b sequence in the same intron of sterol regulatory element-binding transcription factor 1 as humans and express miR-33b similar to humans, exhibit NASH under high-fat diet feeding. This condition is ameliorated by hepatocyte-specific miR-33b deficiency but unaffected by macrophage-specific miR-33b deficiency. Anti-miR-33b oligonucleotide improves the phenotype of NASH in miR-33b KI mice fed a Gubra Amylin NASH diet, which induces miR-33b and worsens NASH more than a high-fat diet. Anti-miR-33b treatment reduces hepatic free cholesterol and triglyceride accumulation through up-regulation of the lipid metabolism-related target genes. Furthermore, it decreases the expression of fibrosis marker genes in cultured hepatic stellate cells. Thus, inhibition of miR-33b using nucleic acid medicine is a promising treatment for NASH.
Collapse
Affiliation(s)
- Sawa Miyagawa
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Takahiro Horie
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Tomohiro Nishino
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Satoshi Koyama
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Toshimitsu Watanabe
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Osamu Baba
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Tomohiro Yamasaki
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Naoya Sowa
- Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan
| | - Chiharu Otani
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Kazuki Matsushita
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Hidenori Kojima
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masahiro Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yasuhiro Nakashima
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Satoshi Obika
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
- Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
| | - Yuuya Kasahara
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
- Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan
| | - Jun Kotera
- Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, Fujisawa-shi, Japan
| | - Kozo Oka
- Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, Fujisawa-shi, Japan
| | - Ryo Fujita
- Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, Fujisawa-shi, Japan
| | - Takashi Sasaki
- Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, Fujisawa-shi, Japan
| | - Akihiro Takemiya
- Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, Fujisawa-shi, Japan
| | - Koji Hasegawa
- Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan
| | - Takeshi Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
4
|
Horie T, Nakao T, Miyasaka Y, Nishino T, Matsumura S, Nakazeki F, Ide Y, Kimura M, Tsuji S, Rodriguez RR, Watanabe T, Yamasaki T, Xu S, Otani C, Miyagawa S, Matsushita K, Sowa N, Omori A, Tanaka J, Nishimura C, Nishiga M, Kuwabara Y, Baba O, Watanabe S, Nishi H, Nakashima Y, Picciotto MR, Inoue H, Watanabe D, Nakamura K, Sasaki T, Kimura T, Ono K. microRNA-33 maintains adaptive thermogenesis via enhanced sympathetic nerve activity. Nat Commun 2021; 12:843. [PMID: 33594062 PMCID: PMC7886914 DOI: 10.1038/s41467-021-21107-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Accepted: 01/12/2021] [Indexed: 12/30/2022] Open
Abstract
Adaptive thermogenesis is essential for survival, and therefore is tightly regulated by a central neural circuit. Here, we show that microRNA (miR)-33 in the brain is indispensable for adaptive thermogenesis. Cold stress increases miR-33 levels in the hypothalamus and miR-33−/− mice are unable to maintain body temperature in cold environments due to reduced sympathetic nerve activity and impaired brown adipose tissue (BAT) thermogenesis. Analysis of miR-33f/f dopamine-β-hydroxylase (DBH)-Cre mice indicates the importance of miR-33 in Dbh-positive cells. Mechanistically, miR-33 deficiency upregulates gamma-aminobutyric acid (GABA)A receptor subunit genes such as Gabrb2 and Gabra4. Knock-down of these genes in Dbh-positive neurons rescues the impaired cold-induced thermogenesis in miR-33f/fDBH-Cre mice. Conversely, increased gene dosage of miR-33 in mice enhances thermogenesis. Thus, miR-33 in the brain contributes to maintenance of BAT thermogenesis and whole-body metabolism via enhanced sympathetic nerve tone through suppressing GABAergic inhibitory neurotransmission. This miR-33-mediated neural mechanism may serve as a physiological adaptive defense mechanism for several stresses including cold stress. Adaptive thermogenesis is regulated by central neuronal circuits. Here, the authors show that microRNA-33 in the brain contributes to the maintenance of brown adipose tissue thermogenesis and whole-body energy balance via enhanced sympathetic nerve tone, and regulating the expression of GABAa receptor subunits.
Collapse
Affiliation(s)
- Takahiro Horie
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
| | - Tetsushi Nakao
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yui Miyasaka
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Tomohiro Nishino
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Shigenobu Matsumura
- Laboratory of Physiological Functions of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto, Japan
| | - Fumiko Nakazeki
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yuya Ide
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masahiro Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Shuhei Tsuji
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Randolph Ruiz Rodriguez
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Toshimitsu Watanabe
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Tomohiro Yamasaki
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Sijia Xu
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Chiharu Otani
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Sawa Miyagawa
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Kazuki Matsushita
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Naoya Sowa
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Aoi Omori
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Jin Tanaka
- Laboratory of Physiological Functions of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto, Japan
| | - Chika Nishimura
- Department of Biological Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masataka Nishiga
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yasuhide Kuwabara
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Osamu Baba
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Shin Watanabe
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Hitoo Nishi
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yasuhiro Nakashima
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Marina R Picciotto
- Department of Psychiatry and Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, CT, USA
| | - Haruhisa Inoue
- Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.,iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.,Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan
| | - Dai Watanabe
- Department of Biological Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Kazuhiro Nakamura
- Department of Integrative Physiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Tsutomu Sasaki
- Laboratory of Nutrition Chemistry, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto, Japan
| | - Takeshi Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
| |
Collapse
|
5
|
Kuwabara Y, Tsuji S, Nishiga M, Izuhara M, Ito S, Nagao K, Horie T, Watanabe S, Koyama S, Kiryu H, Nakashima Y, Baba O, Nakao T, Nishino T, Sowa N, Miyasaka Y, Hatani T, Ide Y, Nakazeki F, Kimura M, Yoshida Y, Inada T, Kimura T, Ono K. Lionheart LincRNA alleviates cardiac systolic dysfunction under pressure overload. Commun Biol 2020; 3:434. [PMID: 32792557 PMCID: PMC7426859 DOI: 10.1038/s42003-020-01164-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Accepted: 07/22/2020] [Indexed: 12/05/2022] Open
Abstract
Recent high-throughput approaches have revealed a vast number of transcripts with unknown functions. Many of these transcripts are long noncoding RNAs (lncRNAs), and intergenic region-derived lncRNAs are classified as long intergenic noncoding RNAs (lincRNAs). Although Myosin heavy chain 6 (Myh6) encoding primary contractile protein is down-regulated in stressed hearts, the underlying mechanisms are not fully clarified especially in terms of lincRNAs. Here, we screen upregulated lincRNAs in pressure overloaded hearts and identify a muscle-abundant lincRNA termed Lionheart. Compared with controls, deletion of the Lionheart in mice leads to decreased systolic function and a reduction in MYH6 protein levels following pressure overload. We reveal decreased MYH6 results from an interaction between Lionheart and Purine-rich element-binding protein A after pressure overload. Furthermore, human LIONHEART levels in left ventricular biopsy specimens positively correlate with cardiac systolic function. Our results demonstrate Lionheart plays a pivotal role in cardiac remodeling via regulation of MYH6. Kuwabara et al. identify a novel long intergenic noncoding RNA (lincRNA), termed Lionheart, upregulated in pressure overloaded hearts in mice. Deleting this gene results in decreased systolic function and reduction in MYH6 protein levels following pressure overload. They demonstrate that Lionheart interacts with PURA, preventing its binding to the promoter region of Myh6 locus, leading to reduced MYH6 protein expression.
Collapse
Affiliation(s)
- Yasuhide Kuwabara
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Shuhei Tsuji
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masataka Nishiga
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masayasu Izuhara
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Shinji Ito
- Medical Research Support Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Kazuya Nagao
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Takahiro Horie
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Shin Watanabe
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Satoshi Koyama
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Hisanori Kiryu
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, University of Tokyo, Chiba, Japan
| | - Yasuhiro Nakashima
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Osamu Baba
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Tetsushi Nakao
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Tomohiro Nishino
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Naoya Sowa
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yui Miyasaka
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Takeshi Hatani
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.,Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
| | - Yuya Ide
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Fumiko Nakazeki
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masahiro Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yoshinori Yoshida
- Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
| | - Tsukasa Inada
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Takeshi Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
| |
Collapse
|
6
|
Nagao K, Tamura A, Sato Y, Hata R, Kawase Y, Kadota K, Horie T, Sowa N, Nishiga M, Ono K, Inada T, Tanaka M. Utility of collagen-derived peptides as markers of organ injury in patients with acute heart failure. Open Heart 2020; 7:e001041. [PMID: 32341786 PMCID: PMC7174059 DOI: 10.1136/openhrt-2019-001041] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2019] [Revised: 02/12/2020] [Accepted: 02/17/2020] [Indexed: 12/28/2022] Open
Abstract
Objective This study aims to investigate the time-dependent prognostic utility of two fibrosis markers representing organ fibrogenesis (N-terminal propeptide of procollagen III (PIIINP) and type IV collagen 7S (P4NP 7S)) in patients with acute heart failure (HF). Methods 390 patients with acute HF were dichotomised based on the median value of fibrosis markers at discharge. The primary outcome measure was a composite of cardiac death and HF hospitalisation. Results P4NP 7S significantly declined during hospitalisation, whereas PIIINP did not. The cumulative 90-day and 365-day incidence of the primary outcome measure was 16.6% vs 16.0% (p=0.42) and 33.3% vs 28.4% (p=0.34) in the patients with high versus low PIIINP; 19.9% vs 13.0% (p=0.04) and 32.3% vs 29.0% (p=0.34) in the patients with high and low P4NP 7S, respectively. After adjusting for confounders, high P4NP 7S correlated with significant excess risk relative to low P4NP 7S for both 90-day and 365-day primary outcome measure (adjusted HR, 1.50; 95% CI, 1.02 to 2.21; p=0.04 and adjusted HR, 1.89; 95% CI, 1.11 to 3.26; p=0.02, respectively), which was driven by significant association of high P4NP 7S with higher incidence of HF hospitalisation. Furthermore, P4NP 7S exhibited an additive value to conventional prognostic factors for predicting 90-day outcome (p=0.038 for net reclassification improvement; p=0.0068 for integrated discrimination improvement). High PIIINP did not correlate with significant excess risk for both 90-day and 365-day outcome. Conclusions This study suggests a possible role of P4NP 7S in the risk stratification of patients with acute HF.
Collapse
Affiliation(s)
- Kazuya Nagao
- Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Akinori Tamura
- Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Yukihito Sato
- Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | - Reo Hata
- Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan
| | - Yuichi Kawase
- Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan
| | - Kazushige Kadota
- Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan
| | - Takahiro Horie
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Naoya Sowa
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Masataka Nishiga
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Tsukasa Inada
- Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Masaru Tanaka
- Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| |
Collapse
|
7
|
Nishino T, Horie T, Baba O, Sowa N, Hanada R, Kuwabara Y, Nakao T, Nishiga M, Nishi H, Nakashima Y, Nakazeki F, Ide Y, Koyama S, Kimura M, Nagata M, Yoshida K, Takagi Y, Nakamura T, Hasegawa K, Miyamoto S, Kimura T, Ono K. SREBF1/MicroRNA-33b Axis Exhibits Potent Effect on Unstable Atherosclerotic Plaque Formation In Vivo. Arterioscler Thromb Vasc Biol 2019; 38:2460-2473. [PMID: 30354203 DOI: 10.1161/atvbaha.118.311409] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Objective- Atherosclerosis is a common disease caused by a variety of metabolic and inflammatory disturbances. MicroRNA (miR)-33a within SREBF2 (sterol regulatory element-binding factor 2) is a potent target for treatment of atherosclerosis through regulating both aspects; however, the involvement of miR-33b within SREBF1 remains largely unknown. Although their host genes difference could lead to functional divergence of miR-33a/b, we cannot dissect the roles of miR-33a/b in vivo because of lack of miR-33b sequences in mice, unlike human. Approach and Results- Here, we analyzed the development of atherosclerosis using miR-33b knock-in humanized mice under apolipoprotein E-deficient background. MiR-33b is prominent both in human and mice on atheroprone condition. MiR-33b reduced serum high-density lipoprotein cholesterol levels and systemic reverse cholesterol transport. MiR-33b knock-in macrophages showed less cholesterol efflux capacity and higher inflammatory state via regulating lipid rafts. Thus, miR-33b promotes vulnerable atherosclerotic plaque formation. Furthermore, bone marrow transplantation experiments strengthen proatherogenic roles of macrophage miR-33b. Conclusions- Our data demonstrated critical roles of SREBF1-miR-33b axis on both lipid profiles and macrophage phenotype remodeling and indicate that miR-33b is a promising target for treating atherosclerosis.
Collapse
Affiliation(s)
- Tomohiro Nishino
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Takahiro Horie
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Osamu Baba
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Naoya Sowa
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Ritsuko Hanada
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Yasuhide Kuwabara
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Tetsushi Nakao
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Masataka Nishiga
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Hitoo Nishi
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Yasuhiro Nakashima
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Fumiko Nakazeki
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Yuya Ide
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Satoshi Koyama
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Masahiro Kimura
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Manabu Nagata
- Neurosurgery (M.N., K.Y., Y.T., S.M.), Graduate School of Medicine, Kyoto University, Japan
| | - Kazumichi Yoshida
- Neurosurgery (M.N., K.Y., Y.T., S.M.), Graduate School of Medicine, Kyoto University, Japan
| | - Yasushi Takagi
- Neurosurgery (M.N., K.Y., Y.T., S.M.), Graduate School of Medicine, Kyoto University, Japan
| | - Tomoyuki Nakamura
- Department of Pharmacology, Kansai Medical University, Moriguchi, Japan (T.N.)
| | - Koji Hasegawa
- Division of Translational Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan (K.H.)
| | - Susumu Miyamoto
- Neurosurgery (M.N., K.Y., Y.T., S.M.), Graduate School of Medicine, Kyoto University, Japan
| | - Takeshi Kimura
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| | - Koh Ono
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., N.S., R.H., Y.K., T.N., M.N., H.N., Y.N., F.N., Y.I., S.K., M.K., T.K., K.O.), Graduate School of Medicine, Kyoto University, Japan
| |
Collapse
|
8
|
Koyama S, Horie T, Nishino T, Baba O, Sowa N, Miyasaka Y, Kuwabara Y, Nakao T, Nishiga M, Nishi H, Nakashima Y, Nakazeki F, Ide Y, Kimura M, Tsuji S, Ruiz Rodriguez R, Xu S, Yamasaki T, Otani C, Watanabe T, Nakamura T, Hasegawa K, Kimura T, Ono K. Identification of Differential Roles of MicroRNA-33a and -33b During Atherosclerosis Progression With Genetically Modified Mice. J Am Heart Assoc 2019; 8:e012609. [PMID: 31242815 PMCID: PMC6662357 DOI: 10.1161/jaha.119.012609] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Background MicroRNA (miR)‐33 targets cholesterol transporter ATP‐binding cassette protein A1 and other antiatherogenic targets and contributes to atherogenic progression. Its inhibition or deletion is known to result in the amelioration of atherosclerosis in mice. However, mice lack the other member of the miR‐33 family, miR‐33b, which exists in humans and other large mammals. Thus, precise evaluation and comparison of the responsibilities of these 2 miRs during the progression of atherosclerosis has not been reported, although they are essential. Methods and Results In this study, we performed a comprehensive analysis of the difference between the function of miR‐33a and miR‐33b using genetically modified mice. We generated 4 strains with or without miR‐33a and miR‐33b. Comparison between mice with only miR‐33a (wild‐type mice) and mice with only miR‐33b (miR‐33a−/−/miR‐33b+/+) revealed the dominant expression of miR‐33b in the liver. To evaluate the whole body atherogenic potency of miR‐33a and miR‐33b, we developed apolipoprotein E–deficient/miR‐33a+/+/miR‐33b−/− mice and apolipoprotein E–deficient/miR‐33a−/−/miR‐33b+/+ mice. With a high‐fat and high‐cholesterol diet, the apolipoprotein E–deficient/miR‐33a−/−/miR‐33b+/+ mice developed increased atherosclerotic plaque versus apolipoprotein E–deficient/miR‐33a+/+/miR‐33b−/− mice, in line with the predominant expression of miR‐33b in the liver and worsened serum cholesterol profile. By contrast, a bone marrow transplantation study showed no significant difference, which was consistent with the relevant expression levels of miR‐33a and miR‐33b in bone marrow cells. Conclusions The miR‐33 family exhibits differences in distribution and regulation and particularly in the progression of atherosclerosis; miR‐33b would be more potent than miR‐33a.
Collapse
Affiliation(s)
- Satoshi Koyama
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Takahiro Horie
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Tomohiro Nishino
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Osamu Baba
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Naoya Sowa
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Yui Miyasaka
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Yasuhide Kuwabara
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Tetsushi Nakao
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Masataka Nishiga
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Hitoo Nishi
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Yasuhiro Nakashima
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Fumiko Nakazeki
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Yuya Ide
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Masahiro Kimura
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Shuhei Tsuji
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Randolph Ruiz Rodriguez
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Sijia Xu
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Tomohiro Yamasaki
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Chiharu Otani
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Toshimitsu Watanabe
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Tomoyuki Nakamura
- 2 Department of Pharmacology Kansai Medical University Hirakata Japan
| | - Koji Hasegawa
- 3 Division of Translational Research Clinical Research Institute National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Takeshi Kimura
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| | - Koh Ono
- 1 Department of Cardiovascular Medicine Graduate School of Medicine Kyoto University Kyoto Japan
| |
Collapse
|
9
|
Yoshikawa Y, Shiomi H, Kuwahara K, Sowa N, Yaku H, Yamashita Y, Tazaki J, Imai M, Kato T, Saito N, Shizuta S, Ono K, Kimura T. Utility of copeptin for predicting long-term clinical outcomes in patients with heart failure. J Cardiol 2018; 73:379-385. [PMID: 30591319 DOI: 10.1016/j.jjcc.2018.11.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 10/04/2018] [Accepted: 11/22/2018] [Indexed: 02/07/2023]
Abstract
BACKGROUND Copeptin, a surrogate marker of pro-arginine vasopressin, is expected to be a marker in cardiovascular diseases. Its utility for predicting long-term clinical outcomes in heart failure (HF), however, has not been adequately evaluated in daily clinical practice in Japan. METHODS To assess the relationship of serum copeptin at admission with long-term clinical outcomes, we evaluated serum copeptin at admission in consecutive 107 patients hospitalized for HF between April 2011 and July 2012. The primary outcome measure was defined as a composite of all-cause death and re-admission for HF (all-cause death/HF). RESULTS In this study population, median serum copeptin at admission was 15.5 (6.7-32.0)pmol/L. As compared with the low-copeptin group (<18pmol/L, N=60), the high-copeptin group (≥18pmol/L, N=47) included more male patients and those with prior myocardial infarction, prior HF, low left ventricular ejection fraction, and chronic kidney disease. During median 4.5 (1.0-5.5) years of clinical follow-up, the cumulative incidence of all-cause death/HF was significantly higher in the high-copeptin than in the low-copeptin group (63.4% versus 33.0% at 1 year, and 85.2% versus 77.2% at 5 years, log-rank p=0.03). After adjusting for confounders, high-copeptin was still an independent predictor for all-cause death/HF [hazard ratio (95% confidence interval): 1.77 (1.04-3.01), p=0.03]. CONCLUSION Copeptin was suggested as a useful marker for predicting long-term clinical outcomes in patients with HF.
Collapse
Affiliation(s)
- Yusuke Yoshikawa
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Hiroki Shiomi
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
| | - Koichiro Kuwahara
- Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan
| | - Naoya Sowa
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Hidenori Yaku
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Yugo Yamashita
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Junichi Tazaki
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Masao Imai
- Division of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | - Takao Kato
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Naritatsu Saito
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Satoshi Shizuta
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Takeshi Kimura
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| |
Collapse
|
10
|
Nagao K, Inada T, Tamura A, Kajitani K, Shimamura K, Yukawa H, Aida K, Sowa N, Nishiga M, Horie T, Makita T, Ono K, Tanaka M. Circulating markers of collagen types I, III, and IV in patients with dilated cardiomyopathy: relationships with myocardial collagen expression. ESC Heart Fail 2018; 5:1044-1051. [PMID: 30273997 PMCID: PMC6301156 DOI: 10.1002/ehf2.12360] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Revised: 06/21/2018] [Accepted: 08/30/2018] [Indexed: 12/28/2022] Open
Abstract
Aims Collagen‐derived peptides such as collagen I C‐terminal telopeptide (CITP) and procollagen III N‐terminal propeptide (PIIINP) have been conventionally used as markers of cardiac fibrosis. Collagen IV 7S domain (P4NP 7S) has been recently reported to be correlated with haemodynamics in patients with acute heart failure. We investigated whether these markers reflect cardiac remodelling and myocardial collagen expression. Methods and results In 80 patients with dilated cardiomyopathy, relationships of CITP, PIIINP, and P4NP 7S to clinical and echocardiographic variables were analysed. CITP and PIIINP were inversely correlated with estimated glomerular filtration rate (r = −0.41, P < 0.001 and r = −0.32, P = 0.004, respectively); P4NP 7S was positively correlated with B‐type natriuretic peptide (r = 0.32, P = 0.003) and γ‐glutamyltransferase (r = 0.38, P < 0.001). These correlations were significant even after adjustment by potential confounders, whereas all three collagen markers were not independently correlated with ejection fraction nor with left ventricular (LV) diastolic diameter. In 33 patients undergoing endomyocardial biopsy, myocardial collagen I and III mRNA expressions were correlated with LV end‐diastolic volume index (r = 0.42, P = 0.02 and r = 0.54, P = 0.002, respectively), whereas myocardial collagen IV mRNA expression was not correlated with LV end‐diastolic volume index nor with ejection fraction. Each collagen‐derived peptide was not significantly correlated with the myocardial expression of their corresponding collagen mRNA. Conclusions Our study shows that CITP, PIIINP, and P4NP 7S do not reflect myocardial collagen mRNA expression but presumably reflect extra‐cardiac organ injury in heart failure.
Collapse
Affiliation(s)
- Kazuya Nagao
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Tsukasa Inada
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Akinori Tamura
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Kenji Kajitani
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Kiyotaka Shimamura
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Hiroshi Yukawa
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Kenji Aida
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Naoya Sowa
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Masataka Nishiga
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Takahiro Horie
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Toshinori Makita
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Masaru Tanaka
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| |
Collapse
|
11
|
Tamura A, Nagao K, Sowa N, Nishiga M, Horie T, Ono K, Inada T, Tanaka M. P882Circulating markers of collagen I, III and IV turnover in patients with dilated cardiomyopathy: time-course change and relationships with myocardial collagen expression. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- A Tamura
- Osaka Red Cross Hospital, Cardiovascular Center, Osaka, Japan
| | - K Nagao
- Osaka Red Cross Hospital, Cardiovascular Center, Osaka, Japan
| | - N Sowa
- Kyoto University Graduate School of Medicine, Department of Cardiovascular Medicine, Kyoto, Japan
| | - M Nishiga
- Kyoto University Graduate School of Medicine, Department of Cardiovascular Medicine, Kyoto, Japan
| | - T Horie
- Kyoto University Graduate School of Medicine, Department of Cardiovascular Medicine, Kyoto, Japan
| | - K Ono
- Kyoto University Graduate School of Medicine, Department of Cardiovascular Medicine, Kyoto, Japan
| | - T Inada
- Osaka Red Cross Hospital, Cardiovascular Center, Osaka, Japan
| | - M Tanaka
- Osaka Red Cross Hospital, Cardiovascular Center, Osaka, Japan
| |
Collapse
|
12
|
Nakazeki F, Nishiga M, Horie T, Nishi H, Nakashima Y, Baba O, Kuwabara Y, Nishino T, Nakao T, Ide Y, Koyama S, Kimura M, Tsuji S, Sowa N, Yoshida S, Conway SJ, Yanagita M, Kimura T, Ono K. Loss of periostin ameliorates adipose tissue inflammation and fibrosis in vivo. Sci Rep 2018; 8:8553. [PMID: 29867212 PMCID: PMC5986813 DOI: 10.1038/s41598-018-27009-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Accepted: 05/23/2018] [Indexed: 12/13/2022] Open
Abstract
Recent evidence suggests that the accumulation of macrophages as a result of obesity-induced adipose tissue hypoxia is crucial for the regulation of tissue fibrosis, but the molecular mechanisms underlying adipose tissue fibrosis are still unknown. In this study, we revealed that periostin (Postn) is produced at extraordinary levels by adipose tissue after feeding with a high-fat diet (HFD). Postn was secreted at least from macrophages in visceral adipose tissue during the development of obesity, possibly due to hypoxia. Postn-/- mice had lower levels of crown-like structure formation and fibrosis in adipose tissue and were protected from liver steatosis. These mice also showed amelioration in systemic insulin resistance compared with HFD-fed WT littermates. Mice deficient in Postn in their hematopoietic compartment also had lower levels of inflammation in adipose tissue, in parallel with a reduction in ectopic lipid accumulation compared with the controls. Our data indicated that the regulation of Postn in visceral fat could be beneficial for the maintenance of healthy adipose tissue in obesity.
Collapse
Affiliation(s)
- Fumiko Nakazeki
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Masataka Nishiga
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Takahiro Horie
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Hitoo Nishi
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Yasuhiro Nakashima
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Osamu Baba
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Yasuhide Kuwabara
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Tomohiro Nishino
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Tetsushi Nakao
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Yuya Ide
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Satoshi Koyama
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Masahiro Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Shuhei Tsuji
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Naoya Sowa
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Shigeo Yoshida
- Department of Ophthalmology, Kyushu University Graduate School of Medical Sciences, Fukuoka, 812-8582, Japan
| | - Simon J Conway
- Herman B Wells Center for Pediatric Research, Indiana University of Medicine, Indianapolis, Indiana, USA
| | - Motoko Yanagita
- Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Takeshi Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
| |
Collapse
|
13
|
Nakao T, Horie T, Baba O, Nishiga M, Nishino T, Izuhara M, Kuwabara Y, Nishi H, Usami S, Nakazeki F, Ide Y, Koyama S, Kimura M, Sowa N, Ohno S, Aoki H, Hasegawa K, Sakamoto K, Minatoya K, Kimura T, Ono K. Genetic Ablation of MicroRNA-33 Attenuates Inflammation and Abdominal Aortic Aneurysm Formation via Several Anti-Inflammatory Pathways. Arterioscler Thromb Vasc Biol 2017; 37:2161-2170. [PMID: 28882868 DOI: 10.1161/atvbaha.117.309768] [Citation(s) in RCA: 66] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2017] [Accepted: 08/21/2017] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Abdominal aortic aneurysm (AAA) is an increasingly prevalent and ultimately fatal disease with no effective pharmacological treatment. Because matrix degradation induced by vascular inflammation is the major pathophysiology of AAA, attenuation of this inflammation may improve its outcome. Previous studies suggested that miR-33 (microRNA-33) inhibition and genetic ablation of miR-33 increased serum high-density lipoprotein cholesterol and attenuated atherosclerosis. APPROACH AND RESULTS MiR-33a-5p expression in central zone of human AAA was higher than marginal zone. MiR-33 deletion attenuated AAA formation in both mouse models of angiotensin II- and calcium chloride-induced AAA. Reduced macrophage accumulation and monocyte chemotactic protein-1 expression were observed in calcium chloride-induced AAA walls in miR-33-/- mice. In vitro experiments revealed that peritoneal macrophages from miR-33-/- mice showed reduced matrix metalloproteinase 9 expression levels via c-Jun N-terminal kinase inactivation. Primary aortic vascular smooth muscle cells from miR-33-/- mice showed reduced monocyte chemotactic protein-1 expression by p38 mitogen-activated protein kinase attenuation. Both of the inactivation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase were possibly because of the increase of ATP-binding cassette transporter A1 that is a well-known target of miR-33. Moreover, high-density lipoprotein cholesterol derived from miR-33-/- mice reduced expression of matrix metalloproteinase 9 in macrophages and monocyte chemotactic protein-1 in vascular smooth muscle cells. Bone marrow transplantation experiments indicated that miR-33-deficient bone marrow cells ameliorated AAA formation in wild-type recipients. MiR-33 deficiency in recipient mice was also shown to contribute the inhibition of AAA formation. CONCLUSIONS These data strongly suggest that inhibition of miR-33 will be effective as a novel strategy for treating AAA.
Collapse
Affiliation(s)
- Tetsushi Nakao
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Takahiro Horie
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Osamu Baba
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Masataka Nishiga
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Tomohiro Nishino
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Masayasu Izuhara
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Yasuhide Kuwabara
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Hitoo Nishi
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Shunsuke Usami
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Fumiko Nakazeki
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Yuya Ide
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Satoshi Koyama
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Masahiro Kimura
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Naoya Sowa
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Satoko Ohno
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Hiroki Aoki
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Koji Hasegawa
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Kazuhisa Sakamoto
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Kenji Minatoya
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Takeshi Kimura
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan
| | - Koh Ono
- From the Departments of Cardiovascular Medicine (T.N., T.H., O.B., M.N., T.N., M.I., Y.K., H.N., S.U., F.N., Y.I., S.K., M.K., N.S., T.K., K.O.) and Cardiovascular Surgery (K.S., K.M.), Graduate School of Medicine, Kyoto University, Japan; The Cardiovascular Research Institute, Kurume University, Japan (S.O., H.A.); and Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Japan.
| |
Collapse
|
14
|
Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, Usami S, Izuhara M, Sowa N, Yahagi N, Shimano H, Matsumura S, Inoue K, Marusawa H, Nakamura T, Hasegawa K, Kume N, Yokode M, Kita T, Kimura T, Ono K. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun 2014; 4:2883. [PMID: 24300912 PMCID: PMC3863899 DOI: 10.1038/ncomms3883] [Citation(s) in RCA: 161] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2013] [Accepted: 11/07/2013] [Indexed: 02/07/2023] Open
Abstract
MicroRNAs (miRs) are small non-protein-coding RNAs that bind to specific mRNAs and inhibit translation or promote mRNA degradation. Recent reports have indicated that miR-33, which is located within the intron of sterol regulatory element-binding protein (SREBP) 2, controls cholesterol homoeostasis and may be a potential therapeutic target for the treatment of atherosclerosis. Here we show that deletion of miR-33 results in marked worsening of high-fat diet-induced obesity and liver steatosis. Using miR-33(-/-)Srebf1(+/-) mice, we demonstrate that SREBP-1 is a target of miR-33 and that the mechanisms leading to obesity and liver steatosis in miR-33(-/-) mice involve enhanced expression of SREBP-1. These results elucidate a novel interaction between SREBP-1 and SREBP-2 mediated by miR-33 in vivo.
Collapse
Affiliation(s)
- Takahiro Horie
- 1] Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan [2] Department of Clinical Innovative Medicine, Institute for Advancement of Clinical and Translational Science, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan [3]
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Watanabe S, Horie T, Nagao K, Kuwabara Y, Baba O, Nishi H, Sowa N, Narazaki M, Matsuda T, Takemura G, Wada H, Hasegawa K, Kimura T, Ono K. Cardiac-specific inhibition of kinase activity in calcium/calmodulin-dependent protein kinase kinase-β leads to accelerated left ventricular remodeling and heart failure after transverse aortic constriction in mice. PLoS One 2014; 9:e108201. [PMID: 25255457 PMCID: PMC4177887 DOI: 10.1371/journal.pone.0108201] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2014] [Accepted: 08/19/2014] [Indexed: 12/26/2022] Open
Abstract
Background The mechanism of cardiac energy production against sustained pressure overload remains to be elucidated. Methods and Results We generated cardiac-specific kinase-dead (kd) calcium/calmodulin-dependent protein kinase kinase-β (CaMKKβ) transgenic (α-MHC CaMKKβkd TG) mice using α-myosin heavy chain (α-MHC) promoter. Although CaMKKβ activity was significantly reduced, these mice had normal cardiac function and morphology at baseline. Here, we show that transverse aortic binding (TAC) in α-MHC CaMKKβkd TG mice led to accelerated death and left ventricular (LV) dilatation and dysfunction, which was accompanied by significant clinical signs of heart failure. CaMKKβ downstream signaling molecules, including adenosine monophosphate-activated protein kinase (AMPK), were also suppressed in α-MHC CaMKKβkd TG mice compared with wild-type (WT) mice. The expression levels of peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α, which is a downstream target of both of CaMKKβ and calcium/calmodulin kinases, were also significantly reduced in α-MHC CaMKKβkd TG mice compared with WT mice after TAC. In accordance with these findings, mitochondrial morphogenesis was damaged and creatine phosphate/β-ATP ratios assessed by magnetic resonance spectroscopy were suppressed in α-MHC CaMKKβkd TG mice compared with WT mice after TAC. Conclusions These data indicate that CaMKKβ exerts protective effects on cardiac adaptive energy pooling against pressure-overload possibly through phosphorylation of AMPK and by upregulation of PGC-1α. Thus, CaMKKβ may be a therapeutic target for the treatment of heart failure.
Collapse
Affiliation(s)
- Shin Watanabe
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Takahiro Horie
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Kazuya Nagao
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yasuhide Kuwabara
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Osamu Baba
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Hitoo Nishi
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Naoya Sowa
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Michiko Narazaki
- Department of Systems Science, Graduate School of Informatics, Kyoto University, Kyoto, Japan
| | - Tetsuya Matsuda
- Department of Systems Science, Graduate School of Informatics, Kyoto University, Kyoto, Japan
| | - Genzou Takemura
- Department of Internal Medicine, Asahi University, Gifu, Japan
| | - Hiromichi Wada
- Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan
| | - Koji Hasegawa
- Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan
| | - Takeshi Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- * E-mail:
| |
Collapse
|
16
|
Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, Usami S, Izuhara M, Nakazeki F, Ide Y, Koyama S, Sowa N, Yahagi N, Shimano H, Nakamura T, Hasegawa K, Kume N, Yokode M, Kita T, Kimura T, Ono K. MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. Sci Rep 2014; 4:5312. [PMID: 24931346 PMCID: PMC4058878 DOI: 10.1038/srep05312] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2014] [Accepted: 05/30/2014] [Indexed: 01/21/2023] Open
Abstract
MicroRNAs (miRs) are small non-protein-coding RNAs that bind to specific mRNAs and inhibit translation or promote mRNA degradation. Recent reports, including ours, indicated that miR-33a located within the intron of sterol regulatory element-binding protein (SREBP) 2 controls cholesterol homeostasis and can be a possible therapeutic target for treating atherosclerosis. Primates, but not rodents, express miR-33b from an intron of SREBF1. Therefore, humanized mice, in which a miR-33b transgene is inserted within a Srebf1 intron, are required to address its function in vivo. We successfully established miR-33b knock-in (KI) mice and found that protein levels of known miR-33a target genes, such as ABCA1, ABCG1, and SREBP-1, were reduced compared with those in wild-type mice. As a consequence, macrophages from the miR-33b KI mice had a reduced cholesterol efflux capacity via apoA-I and HDL-C. Moreover, HDL-C levels were reduced by almost 35% even in miR-33b KI hetero mice compared with the control mice. These results indicate that miR-33b may account for lower HDL-C levels in humans than those in mice and that miR-33b is possibly utilized for a feedback mechanism to regulate its host gene SREBF1. Our mice will also aid in elucidating the roles of miR-33a/b in different genetic disease models.
Collapse
Affiliation(s)
- Takahiro Horie
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
- Department of Clinical Innovative Medicine, Institute for Advancement of Clinical and Translational Science, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
- These authors contributed equally to this work
| | - Tomohiro Nishino
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
- These authors contributed equally to this work
| | - Osamu Baba
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Yasuhide Kuwabara
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Tetsushi Nakao
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Masataka Nishiga
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Shunsuke Usami
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Masayasu Izuhara
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Fumiko Nakazeki
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Yuya Ide
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Satoshi Koyama
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Naoya Sowa
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Naoya Yahagi
- Department of Internal Medicine (Endocrinology and Metabolism), Graduate School of Comprehensive Human Sciences, Nutrigenomics Research Group, Faculty of Medicine, and International Institute for Integrative Sleep Medicine (IIIS), World Premir International Research Center Initiative (WPI), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
| | - Hitoshi Shimano
- Department of Internal Medicine (Endocrinology and Metabolism), Graduate School of Comprehensive Human Sciences, Nutrigenomics Research Group, Faculty of Medicine, and International Institute for Integrative Sleep Medicine (IIIS), World Premir International Research Center Initiative (WPI), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
| | - Tomoyuki Nakamura
- Department of Pharmacology, Kansai Medical University, Moriguchi, Osaka 570-8506, Japan
| | - Koji Hasegawa
- Division of Translational Research, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Noriaki Kume
- Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 650-8586, Japan
| | - Masayuki Yokode
- Department of Clinical Innovative Medicine, Institute for Advancement of Clinical and Translational Science, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Toru Kita
- Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe 650-0046, Japan
| | - Takeshi Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| |
Collapse
|
17
|
Nagao K, Sowa N, Inoue K, Tokunaga M, Fukuchi K, Uchiyama K, Ito H, Hayashi F, Makita T, Inada T, Tanaka M, Kimura T, Ono K. Myocardial expression level of neural cell adhesion molecule correlates with reduced left ventricular function in human cardiomyopathy. Circ Heart Fail 2013; 7:351-8. [PMID: 24365773 DOI: 10.1161/circheartfailure.113.000939] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
BACKGROUND Recently, we screened for cardiac genes induced by metabolic stress and identified neural cell adhesion molecule (NCAM) as a candidate. This study aimed to clarify the expression pattern of NCAM in human cardiomyopathy. METHODS AND RESULTS A total of 64 cardiac tissue samples of patients with dilated cardiomyopathy were dichotomized according to the immunohistochemically determined signal intensity of NCAM staining (NCAM-high and NCAM-low groups). Clinical and hemodynamic data of the patients were compared between the 2 groups. Fibrosis area, left ventricular end-diastolic volume index, and left ventricular diastolic pressure were greater in the NCAM-high group (22.8% versus 11.6%, P<0.05; 130.3±57.6 versus 104.8±31.7 mL/m(2), P<0.05; 14.3±8.0 versus 8.8±4.7 mm Hg, P<0.005; respectively). Incidence of cardiac death and admission for worsening heart failure was higher in the NCAM-high group during a follow-up of 6.3 years (log-rank P<0.05). Another 18 tissue samples were analyzed to determine the relationships between expression level of NCAM and major metabolic genes as well as hemodynamic parameters. The mRNA level of NCAM correlated with the serum (r=0.58; P=0.01) and mRNA levels (r=0.61; P=0.008) of brain-derived natriuretic peptides. It was also correlated with the mRNA levels of proliferator-activated receptor-γ coactivator-1 α (r=0.69; P=0.002) and the nuclear respiratory factor 1 (r=0.74; P<0.001). CONCLUSIONS Expression of NCAM was associated with worsening hemodynamic parameters and major metabolic genes. Together with our previous findings, these data support the involvement of NCAM in left ventricular remodeling, revealing new insights into the pathophysiology of heart failure.
Collapse
Affiliation(s)
- Kazuya Nagao
- Department of Cardiovascular Center, Osaka Red Cross Hospital, Osaka, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Nagao K, Sowa N, Ito H, Hayashi F, Uchiyama K, Makita T, Inada T, Tanaka M, Kimura T, Ono K. Myocardial expression level of neural cell adhesion molecule correlates with reduced left ventricular function in human cardiomyopathy. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht310.p5731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Sowa N, Horie T, Kuwabara Y, Baba O, Watanabe S, Nishi H, Kinoshita M, Takanabe‐Mori R, Wada H, Shimatsu A, Hasegawa K, Kimura T, Ono K. MicroRNA 26b encoded by the intron of small CTD phosphatase (SCP) 1 has an antagonistic effect on its host gene. J Cell Biochem 2012; 113:3455-65. [DOI: 10.1002/jcb.24222] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Naoya Sowa
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606‐8507, Japan
| | - Takahiro Horie
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606‐8507, Japan
| | - Yasuhide Kuwabara
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606‐8507, Japan
| | - Osamu Baba
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606‐8507, Japan
| | - Shin Watanabe
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606‐8507, Japan
| | - Hitoo Nishi
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606‐8507, Japan
| | - Minako Kinoshita
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606‐8507, Japan
| | - Rieko Takanabe‐Mori
- Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto 612‐8555, Japan
| | - Hiromichi Wada
- Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto 612‐8555, Japan
| | - Akira Shimatsu
- Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto 612‐8555, Japan
| | - Koji Hasegawa
- Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto 612‐8555, Japan
| | - Takeshi Kimura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606‐8507, Japan
| | - Koh Ono
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606‐8507, Japan
| |
Collapse
|
20
|
Takanabe-Mori R, Ono K, Sowa N, Wada H, Takaya T, Horie T, Satoh-Asahara N, Shimatsu A, Fujita M, Sawamura T, Hasegawa K. Lectin-like oxidized low-density lipoprotein receptor-1 is required for the adipose tissue expression of proinflammatory cytokines in high-fat diet-induced obese mice. Biochem Biophys Res Commun 2010; 398:576-80. [PMID: 20599751 DOI: 10.1016/j.bbrc.2010.06.123] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2010] [Accepted: 06/29/2010] [Indexed: 11/30/2022]
Abstract
Lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1) is a receptor for oxidized LDL, and is strongly expressed in endothelial cells at an early stage of atherosclerosis. LOX-1 expression in adipocytes is induced by PPARgamma (ligands and appears to be involved in adipocyte cholesterol metabolism. However, the role of adipose tissue LOX-1 in high-fat diet-induced obesity is unknown. We found that mRNA levels of adipose tissue LOX-1 were markedly increased in obese mice fed a high-fat diet (HFD) compared with those fed normal chow. The levels were closely correlated with those of a proinflammatory cytokine, monocyte chemoattractant protein-1 (MCP-1). Then, LOX-1 knockout (LOX-1-KO) and wild-type (WT) mice were fed HFD for 16weeks. HFD feeding increased the body and mesenteric fat weights similarly in WT and LOX-1-KO mice. HFD-induced expressions of proinflammatory cytokines such as MCP-1, MIP-1alpha, and IL-6 were significantly less in LOX-1-KO than WT mice. Thus, LOX-1 is required for the HFD-induced expression of proinflammatory cytokines in the adipose tissue of obese mice.
Collapse
Affiliation(s)
- Rieko Takanabe-Mori
- Division of Translational Research, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Kawamura T, Ono K, Morimoto T, Akao M, Iwai-Kanai E, Wada H, Sowa N, Kita T, Hasegawa K. Endothelin-1-dependent nuclear factor of activated T lymphocyte signaling associates with transcriptional coactivator p300 in the activation of the B cell leukemia-2 promoter in cardiac myocytes. Circ Res 2004; 94:1492-9. [PMID: 15117818 DOI: 10.1161/01.res.0000129701.14494.52] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Endothelin-1 (ET-1) is a potent survival factor that protects cardiac myocytes from apoptosis. ET-1 induces cardiac gene transcription and protein expression of antiapoptotic B cell leukemia-2 (bcl-2) in a calcineurin-dependent manner. A cellular target of adenovirus early region 1A (E1A) oncoprotein, p300 also activates bcl-2 transcription in cardiac myocytes and is required for their survival. p300 acts as a calcineurin-regulated nuclear factors of activated T lymphocytes (NFATc), downstream targets of calcineurin. In addition, the bcl-2 promoter contains multiple NFAT consensus sequences. These findings prompted us to investigate the role of NFATc in ET-1-dependent and p300-dependent bcl-2 transcription in cardiac myocytes. In primary cardiac myocytes prepared from neonatal rats, mutation of 2 NFAT sites within the bcl-2 promoter completely abolished the ET-1- and p300-induced increases in the activity of this promoter. We show here that p300 markedly potentiates the binding of NFATc1 to the bcl-2 NFAT element by interacting with NFATc1 in an E1A-dependent manner. On the other hand, stimulation of cardiac myocytes with ET-1 causes nuclear translocation of NFATc1, which interacts with p300 and increases DNA binding. Expression of E1A did not change the cardiac nuclear localization of NFATc1 but blocked its interaction with p300, DNA binding, and bcl-2 promoter activation. These findings suggest that ET-1-dependent NFATc signaling associates with p300 in the transactivation of bcl-2 gene in cardiac myocytes.
Collapse
Affiliation(s)
- Teruhisa Kawamura
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Ono K, Iwanaga Y, Hirayama M, Kawamura T, Sowa N, Hasegawa K. Contribution of caveolin-1 alpha and Akt to TNF-alpha-induced cell death. Am J Physiol Lung Cell Mol Physiol 2004; 287:L201-9. [PMID: 15020298 DOI: 10.1152/ajplung.00293.2003] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We used retrovirus insertion-mediated random mutagenesis to generate tumor necrosis factor-alpha (TNF-alpha)-resistant lines from L929 cells. Using this approach, we discovered that caveolin-1 alpha is required for TNF-alpha-induced cell death in L929 cells. The need for caveolin-1 alpha in TNF-alpha-induced cell death was confirmed by the restoration of sensitivity to TNF-alpha after ectopic reconstitution of caveolin-1 alpha/beta expression. This caveolin-1 alpha-mutated line was also resistant to H(2)O(2) and staurosporine, but not to lonidamine. HepG2 cells are known to lack endogenous caveolins. HepG2 cells stably transfected with caveolin-1 alpha/beta were found to be much more sensitive to TNF-alpha than either parental cells transfected with caveolin-1 beta or parental cells transfected with an empty vector. In contrast to its extensively documented antiapoptotic effect, the elevated activity of Akt appears to be important in sensitizing caveolin-1-expressing cells to TNF-alpha, since pretreatment of cells with the phosphatidylinositide 3-kinase (PI3K) inhibitor LY-294002 or wortmannin completely blocked PI3K activation and markedly improved the survival of TNF-alpha-treated L929 cells. The survival rates of caveolin-1 alpha-normal and caveolin-1 alpha-deficient L929 cells were comparable after treatment with PI3K inhibitor and TNF-alpha. Similar results were obtained with HepG2 cells that stably expressed caveolin-1 alpha/beta or -beta and parental cells transfected with an empty vector. In summary, our results indicate that caveolin-1 alpha preferentially sensitizes L929 cells to TNF-alpha through the activation of a PI3K/Akt signaling pathway.
Collapse
Affiliation(s)
- Koh Ono
- Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto 612-8555, Japan.
| | | | | | | | | | | |
Collapse
|
23
|
Abstract
Hemin was covalently connected to two 9-aminoacridines (9AA) through its two propionates, and the binding properties of this bis-dentate compound (hemin(9AA)2) to DNA were examined by visible absorption spectroscopy. The binding affinity of the hemin(9AA)2 was found to be higher than that of the hemin, and this should be attributed to the two linked acridine moieties. The binding constant (K) and the number of binding sites per nucleotide (n) were estimated by Scatchard plot analyses. Though the order of the K value of hemin(9AA)2 was similar to that of 9AA, the hemin(9AA)2 was analyzed to have a smaller n value, the order of which was of about 10(-4). The small n value may reflect the sequence specificity of the bis-dentate hemin(9AA)2 on binding to the DNA.
Collapse
Affiliation(s)
- T Uno
- Faculty of Pharmaceutical Sciences, University of Tokushima, Japan
| | | | | |
Collapse
|
24
|
Morimoto T, Matsushima M, Sowa N, Ide K, Sawanishi K. Plasma adsorption using bilirubin-adsorbent materials as a treatment for patients with hepatic failure. Artif Organs 1989; 13:447-52. [PMID: 2803055 DOI: 10.1111/j.1525-1594.1989.tb01556.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
In order to achieve a higher degree of improvement in patients with postoperative hepatic failure, the effects of plasma adsorption (PA) using a serial connection of noncoated charcoal (N 350) and a new bilirubin adsorbent material, styrenedivinylbenzene (BR350), were investigated both experimentally and clinically. After in vitro perfusion of high bilirubin containing plasma through these columns for 3 hours, total bilirubin levels were drastically reduced to 21% of the preperfusion level in the serial connection of N 350 and BR 350, while it remained high at over 40% in the single use of each column. Total branched chain and aromatic amino acid levels were also drastically reduced in the serial connection of these columns to 50, 40, and 7%, respectively, while the total amino acid levels remained high at 87% in the single use of BR 350. The combination of these columns enhanced rather than interfered with one another. Patients who received this treatment achieved an initial reduction of plasma total bilirubin and aromatic amino acids of 57 +/- 6 and 84 +/- 7, respectively. Although the long-term prognosis for these patients was negative, improvement of clinical and laboratory findings were actually obtained by this treatment. This PA system could provide a possibility for an improved supportive therapy for hepatic failure, especially for patients with hepatic coma and hyperbilirubinemia.
Collapse
Affiliation(s)
- T Morimoto
- Division of Artificial Kidney, Kyoto University Hospital, Japan
| | | | | | | | | |
Collapse
|